| Lenscrafters At Macy's #8531 | |
| 20 Mall Dr E, Jersey City, New Jersey 07310 | |
| (201) 216-0673 |
| Name | Lenscrafters At Macy's #8531 |
|---|---|
| Organization Name | Luxottica Of America Inc |
| Location | 20 Mall Dr E, Jersey City, New Jersey 07310 |
| Type | Eyewear Supplier (Equipment, not the service) |
| Phone | (201) 216-0673 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
With an ever-increasing volume of electronic data being collected by the healthcare system, researchers are exploring the use of machine learning—a subfield of artificial intelligence—to improve medical care and patient outcomes.
QLT Inc. today announced that QLT091001, the Company's oral synthetic retinoid, has been granted orphan drug designation for the treatment of Retinitis Pigmentosa (RP) from the U.S. Food and Drug Administration (FDA). This follows the FDA grant of orphan drug designation for QLT091001 for the treatment of Leber Congenital Amaurosis (LCA) also on December 7, 2010.
Advancing age is a major risk factor for Alzheimer's disease and is associated with build- up of the peptide amyloid β in the brain. New research published in BioMed Central's open access journal Fluids and Barriers of the CNS shows that removal of amyloid β from the brain depends on vitamin D and also on an age-related alteration in the production of transporter proteins which move amyloid β in and out of the brain.
Wayne State University researchers have found that when patients and providers speak the same language, patients report less confusion and better health care quality.
› Verified 4 days ago
| NPI Number | 1306397377 |
| Organization Name | LUXOTTICA OF AMERICA INC. |
| Doing Business As | LENSCRAFTERS #8531 |
| Type | Eyewear Supplier (Equipment, not the service) |
| Address | 20 Mall Dr E, Jersey City, NJ 07310 |
| Phone Number | 201-216-0673 |
News Archive
With an ever-increasing volume of electronic data being collected by the healthcare system, researchers are exploring the use of machine learning—a subfield of artificial intelligence—to improve medical care and patient outcomes.
QLT Inc. today announced that QLT091001, the Company's oral synthetic retinoid, has been granted orphan drug designation for the treatment of Retinitis Pigmentosa (RP) from the U.S. Food and Drug Administration (FDA). This follows the FDA grant of orphan drug designation for QLT091001 for the treatment of Leber Congenital Amaurosis (LCA) also on December 7, 2010.
Advancing age is a major risk factor for Alzheimer's disease and is associated with build- up of the peptide amyloid β in the brain. New research published in BioMed Central's open access journal Fluids and Barriers of the CNS shows that removal of amyloid β from the brain depends on vitamin D and also on an age-related alteration in the production of transporter proteins which move amyloid β in and out of the brain.
Wayne State University researchers have found that when patients and providers speak the same language, patients report less confusion and better health care quality.
› Verified 4 days ago
News Archive
With an ever-increasing volume of electronic data being collected by the healthcare system, researchers are exploring the use of machine learning—a subfield of artificial intelligence—to improve medical care and patient outcomes.
QLT Inc. today announced that QLT091001, the Company's oral synthetic retinoid, has been granted orphan drug designation for the treatment of Retinitis Pigmentosa (RP) from the U.S. Food and Drug Administration (FDA). This follows the FDA grant of orphan drug designation for QLT091001 for the treatment of Leber Congenital Amaurosis (LCA) also on December 7, 2010.
Advancing age is a major risk factor for Alzheimer's disease and is associated with build- up of the peptide amyloid β in the brain. New research published in BioMed Central's open access journal Fluids and Barriers of the CNS shows that removal of amyloid β from the brain depends on vitamin D and also on an age-related alteration in the production of transporter proteins which move amyloid β in and out of the brain.
Wayne State University researchers have found that when patients and providers speak the same language, patients report less confusion and better health care quality.
› Verified 4 days ago
Acme Pharmacy #1083 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 125 18th St, Jersey City, New Jersey 07310 Phone: (201) 418-0585 | |
Acme Pharmacy #1092 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 321 Route 440, Jersey City, New Jersey 07305 Phone: (201) 946-2535 | |
St John's Pharmacy Type: Community/Retail Pharmacy Location: 2980 John F Kennedy Blvd, Jersey City, New Jersey 07306 Phone: (201) 963-3617 | |
Ahmar Pharmacy Type: Pharmacy Location: 53 Baldwin Ave, Jersey City, New Jersey 07304 Phone: (201) 332-9333 | |
Associated Retinal Consultants Llc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 600 Pavonia Ave, Jersey City, New Jersey 07306 Phone: (201) 963-3937 |